



Handelsbanken Hälsovård Tema

Investment Focus

The fund is actively managed, which means that the portfolio manager takes active, independent investment decisions. The long term objective of the fund is to exceed the returns of the underlying market, defined as the benchmark index. Fund returns are determined by how the fund's investments in equities increase or decrease in value. The fund is a global equity fund with the objective of making investments in companies with products or services that contribute to the attainment of the Sustainable Development Goals (as defined in Agenda 2030) in general and, in particular, towards the fulfillment of Goal 3: Good health and well-being. The fund's objective will be attained through investments in companies within the healthcare sector. The healthcare sector refers to pharmaceuticals, medical technology, biotech, service and other healthcare-related sectors such as healthcare-related IT, aesthetics, or preventive care. The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time. Our main themes are Demographics, Productivity, Lifestyles and the Environment. International norms and guidelines for the environment, social responsibility and corporate governance are taken into consideration within the scope of the fund's investment focus. The fund applies an exclusion strategy for companies operating within the fossil fuels, military equipment, tobacco, cannabis, alcohol, commercial gambling and pornography segments/sectors. However, the fund may invest in companies or funds that invest in companies involved in power generation, distribution or services related to fossil fuels in those cases where the company is deemed to be transitioning its operations to more renewable energy. The fund may invest in derivative instruments as part of its investment focus. The fund may invest a maximum of 10% of the fund capital in fund units. We compare the fund's performance with Solactive ISS ESG Screened DM Health Care UCITS Index NTR. As the fund is actively managed the performance will over time deviate from this index. Additional information about the sustainability work, the share class designation in parentheses and the management in relation to the funds benchmark index and risk level, may be found in the prospectus.

Portfolio

The fund rose by 18.8% during H1 2024*. The benchmark index rose by 13.6% over the same period. The fund outperformed its benchmark index after taking into account management fees. This was primarily due to the the fund's holdings within diabetes/obesity that rose sharply following the major breakthroughs made by the obesity drugs from Eli Lilly, Novo Nordisk and Zealand Pharma, which contributed strongly to fund returns. Zealand Pharma was also a strong contributor, with holdings that posted the highest upturn in absolute numbers at +137%. The fund's excess returns came from several areas that included the cancer segment, where Japanese Daiichi Sankyo outsourced the ADC technology (antibody-drug conjugate) to Merck. Cencora, operating with the distribution of drugs, also rose sharply on improved profitability and growth. The recovery after the pandemic benefited the fund's holdings in the hospital company HCA, which is also performing strongly with a higher occupancy. Krystal Biotech received approval for the treatment of a rare skin disease at the end of 2023 and rose sharply on the back of a successful launch in H1 2024. Thus far, three of the fund's holdings have been acquired with a significant premium: Shockwave Medical, Alpine Immune and Calliditas. We believe the acquisition activity among several major pharmaceutical companies can continue as a result of the declining interest rates and the need for companies to supplement the pipeline after patent expirations to ensure further growth. The fund has a number of smaller positions in exciting research companies that after attaining their research targets can be

interesting for acquisitions by established larger companies. On the negative side, the holding in Evotec declined after the resignation of its CEO, as well as due to launch delays. Immunome, which is an early-stage research company in ADCs for rare cancer diseases, has been revaluated given the delays in moving the pipeline further. However, we consider this to be an interesting company over the long term. The holdings in Seres Therapeutics were sold after a downturn and when the launch of their first drug did not meet expectations. We purchased new holdings within the interesting area of radio legends through Australian Telix Pharmaceuticals and within cancer diagnostics through Natera. We also added the research company Merus within cancer and Madrigal, with focus on kidney disease. Overall, returns have been very strong in both absolute and relative terms. We expect the positive performance to continue given that several interesting study results are expected throughout the remainder of the year and the long-term needs for healthcare worldwide are significant.

* The fund may have additional share classes, the concerned share class is stated in the Fund facts. Refer to fund statistics for comparable index

Significant risks

The fund is an equity fund which means a higher risk, but also the potential for a higher return. The investments are made globally, although there may be an emphasis in equities listed in the US, which means that the risk in the fund can be slightly higher than that of a fund with a greater geographic distribution. The fund's investments are concentrated to companies active within healthcare, and as a result, the risk in the fund is normally higher than that of an investment in a diversified fund that distributes its investments across several sectors. The fund has a currency risk, which means that the returns and the risk are affected by changes in exchange rates. The fund has share classes in various currencies, which means that the returns and the risk can vary across different share classes. The fund may invest in derivatives as part of its investment focus to increase returns in the fund and to create leverage. The volume of trading is limited where applicable and is expected to have a marginal impact on the fund's risk profile. A sustainability risk is an environmental-, social-, or corporate governance-related event or condition that, should it occur, could cause an actual or potential significant adverse impact on a company's value. Accordingly, environmental-related, as well as social-, or governance-related events can arise from a company's own business operations or from events that occur independently of the company. The sustainability risks in the fund are systematically measured and followed up. The risk is deemed to be moderate and the actual measurement will be reported in the annual report.

Trading with derivatives

According to the fund rules, the fund may trade with derivatives as part of its investment focus. The fund did not use this option during 2024. The fund has the option of lending securities. The fund did use this option during 2024. The fund may use other techniques and instruments. The fund did not use this option during 2024.

• Highest leverage during the financial year	0.0%
• Lowest leverage during the financial year	0.0%
• Average leverage during the financial year	0.0%

Information

Since the changes in tax regulations for Swedish funds (2012) and due to developments within the area of taxation, it is unclear how foreign distributions will be taxed. More information about foreign withholding taxes can be found at the end of this report.

Shareholder commitments

Based on the Management Company's Policy for shareholder engagement and responsible investment and the Management Company's Voting policy, the Management Company carries out voting at shareholders' meetings, nomination committee work and dialogues held in-house with

Handelsbanken Hälsovård Tema, cont.

the portfolio companies or in collaboration with others. The Management Company's work in nomination committees is also regulated by the Guidelines for nomination committee work. It is our view that this work will improve governance and reduce sustainability risks in the portfolio companies, which in turn will result in positive value growth.

The Management Company ensures that relevant information is available as a basis for analysis and voting decisions. This information is provided through analyses from proxy advisors, as well as through market information, third-party analyses or contact with the company. The Management Company then makes independent decisions on those issues where voting or other decisions are to be taken.

The Management Company primarily votes at the general meetings where the funds own a minimum of 0.5% of the votes, where the companies constitute significant holdings in each fund, where the Management Company determines that a specific engagement effort is necessary in accordance with the Management Company's established sustainability objectives and commitments, at companies with which the Management Company holds dialogues in which the subject of the dialogue will be presented for a decision at the general meeting, at shareholders' meetings where relevant sustainability issues will be presented for a decision, as well as at other general meetings that address principal or controversial issues. The Management Company determines which equities will be lent. For example, equity lending does not occur in companies in which the Management Company has a seat on the nomination committee. In each individual case, the Management Company makes an assessment of whether or not an equity loan will be withdrawn. Securities lending revenues for the fund are weighed against opportunities for shareholder engagement at the general meeting.

Handelsbanken Fonder participates in all nomination committees where we have a sufficiently large ownership to be offered a seat. However, nomination committees are not common outside of the Nordics and the board composition can only be impacted by voting at the shareholders' meetings.


Within its shareholder engagement, Handelsbanken Fonder conducts engagement dialogues with companies to encourage the company to enhance its sustainability work as well as with companies that we believe are not compliant with the international norms and conventions respected by the Management Company.

Engagement work is conducted primarily through direct dialogues between Handelsbanken Fonder and the companies, joint dialogues together with other investors, as well as in collaborations and initiatives with focus on specific sustainability issues.

There have been no conflicts of interest between the Management Company and the portfolio companies in conjunction with the fund's investments. Information about how the Management Company in general addresses conflicts of interest that may arise in conjunction with the fund's investments is available in the Management Company's Policy for shareholder engagement and responsible investment.

Read more about Handelsbanken Fonder's approach to ownership issues and about the Management Company's guidelines for responsible investment in the Company's Policy for shareholder engagement and responsible investment, the Management Company's Voting policy and the Guidelines for nomination committee work, which are available at handelsbankenfonder.se/policy och riktlinjer. The sustainability-related disclosures included as an appendix to the annual report provide additional information about the engagement work in the form of dialogue and corporate governance that has been undertaken by the Management Company on behalf of the fund.

Fund performance *



* The graph is indexed with starting value 100. Performance is shown in the fund's base currency. The fund may have several share classes.

Fund facts - history

	1/1-30/6 2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Net asset value, SEK										
Hälsovård Tema A1 - SEK	479.97	403.97	394.08	363.71	294.14	266.14	205.29	181.56	160.73	158.53
Hälsovård Tema A1 - EUR	42.29	36.29	35.44	35.33	29.27	25.33	20.26	18.47	16.77	17.31
Hälsovård Tema A1 - NOK	482.56	407.08	372.57	354.35	306.75	249.88	-	181.38	152.29	166.44
Hälsovård Tema A9 - SEK	179.04	150.13	145.36	134.00	107.55	-	-	-	-	-
Hälsovård Tema A9 - EUR	43.64	37.31	36.16	35.78	29.43	-	-	-	-	-
Hälsovård Tema A10 - SEK	501.97	420.59	406.62	371.91	298.09	267.29	-	-	-	-
Hälsovård Tema A10 - EUR	43.72	37.35	36.14	35.61	29.24	-	-	-	-	-
Hälsovård Tema A10 - NOK	504.68	423.84	384.43	362.24	310.77	250.90	-	-	-	-
Hälsovård Tema B1 - SEK	202.59	176.70	178.82	170.88	143.22	135.00	107.89	-	-	-
The fund's total net flow, SEK m	2,216	-1,294	1,824	2,006	2,021	2,241	2,108	72	-683	98
Fund capital total, SEK m										
Hälsovård Tema A1 - SEK	24,102	18,336	19,189	16,019	11,103	8,200	4,449	2,179	1,884	2,582
Hälsovård Tema A1 - EUR	20,297	15,084	15,541	12,743	8,910	7,180	4,146	2,073	1,784	2,348
Hälsovård Tema A1 - NOK	44	40	44	38	28	20	13	11	10	26
Hälsovård Tema A9 - SEK	89	60	64	45	54	8	-	0	0	0
Hälsovård Tema A9 - EUR	502	620	1,039	991	794	-	-	-	-	-
Hälsovård Tema A9 - SEK	5	5	5	5	3	-	-	-	-	-
Hälsovård Tema A10 - SEK	1,658	1,149	962	751	503	386	-	-	-	-
Hälsovård Tema A10 - EUR	1	1	2	2	2	-	-	-	-	-
Hälsovård Tema A10 - NOK	362	279	273	302	36	82	-	-	-	-
Hälsovård Tema B1 - SEK	627	643	723	709	484	330	168	-	-	-
Number of units total, 1000's										
Hälsovård Tema A1 - SEK	53,573	49,889	55,314	50,847	44,140	32,006	22,411	12,004	11,719	16,289
Hälsovård Tema A1 - EUR	42,288	37,340	39,436	35,037	30,290	26,980	20,197	11,418	11,101	14,808
Hälsovård Tema A1 - NOK	1,042	1,093	1,243	1,081	964	783	655	586	618	1,481
Hälsovård Tema A9 - SEK	184	147	170	128	177	31	-	0	0	0
Hälsovård Tema A9 - EUR	2,805	4,129	7,148	7,398	7,384	-	-	-	-	-
Hälsovård Tema A9 - SEK	115	122	125	143	90	-	-	-	-	-
Hälsovård Tema A10 - SEK	3,304	2,733	2,366	2,018	1,688	1,444	-	-	-	-
Hälsovård Tema A10 - EUR	24	27	69	61	53	-	-	-	-	-
Hälsovård Tema A10 - NOK	717	659	710	834	116	326	-	-	-	-
Hälsovård Tema B1 - SEK	3,095	3,640	4,046	4,147	3,379	2,442	1,559	-	-	-
Total returns in %										
Hälsovård Tema A1 - SEK	18.8	2.5	8.4	23.6	10.5	29.6	13.1	13.0	1.4	11.5
Hälsovård Tema A1 - EUR	16.5	2.4	0.3	20.7	15.6	25.0	9.7	10.1	-3.1	15.3
Hälsovård Tema A1 - NOK	18.5	9.3	5.1	15.5	22.8	24.6	10.5	19.1	-8.5	22.2

Handelsbanken Hälsövärd Tema, cont.

Hälsövärd Tema A9 - SEK	19.3	3.3	8.5	24.6	7.6	-	-	-	-	-
Hälsövärd Tema A9 - EUR	17.0	3.2	1.1	21.6	13.0	-	-	-	-	-
Hälsövärd Tema A10 - SEK	19.3	3.4	9.3	24.8	11.5	-	-	-	-	-
Hälsövärd Tema A10 - EUR	17.1	3.3	1.5	21.8	16.6	-	-	-	-	-
Hälsövärd Tema A10 - NOK	19.1	10.3	6.1	16.6	23.9	-	-	-	-	-
Hälsövärd Tema B1 - SEK	18.8	2.5	8.3	23.6	10.7	29.6	13.1	13.0	1.4	11.5
Index including dividends in %										
Hälsövärd Tema A1 - SEK	13.6	0.4	10.0	33.2	-1.9	30.7	11.0	8.0	0.4	14.8
Hälsövärd Tema A1 - EUR	11.5	0.3	1.8	30.0	2.6	26.0	7.7	5.2	-4.0	18.7
Hälsövärd Tema A1 - NOK	13.4	7.0	6.8	24.5	8.9	25.6	8.5	13.8	-9.4	25.8
Hälsövärd Tema A9 - SEK	13.6	0.4	10.0	33.2	-5.8	-	-	-	-	-
Hälsövärd Tema A9 - EUR	11.5	0.3	1.8	30.0	-1.1	-	-	-	-	-
Hälsövärd Tema A10 - SEK	13.6	0.4	10.0	33.2	-1.9	-	-	-	-	-
Hälsövärd Tema A10 - EUR	11.5	0.3	1.8	30.0	2.6	-	-	-	-	-
Hälsövärd Tema A10 - NOK	13.4	7.0	6.8	24.5	8.9	-	-	-	-	-
Hälsövärd Tema B1 - SEK	13.6	0.4	10.0	33.2	-1.9	30.7	11.0	8.0	0.4	14.8
Tracking error, 2 yrs. %										
Hälsövärd Tema A1 - SEK	1.9	2.7	4.7	5.2	3.5	3.6	3.5	3.7	3.6	2.6
Hälsövärd Tema A1 - EUR	1.9	2.7	4.7	5.2	3.5	3.6	3.5	3.7	3.6	2.6
Hälsövärd Tema A1 - NOK	1.9	2.7	4.7	5.2	3.5	3.6	-	3.7	3.6	2.6
Hälsövärd Tema A9 - SEK	1.9	2.8	4.8	-	-	-	-	-	-	-
Hälsövärd Tema A9 - EUR	1.9	2.7	4.7	-	-	-	-	-	-	-
Hälsövärd Tema A10 - SEK	1.9	2.7	4.7	5.2	-	-	-	-	-	-
Hälsövärd Tema A10 - EUR	1.9	2.7	4.8	5.2	-	-	-	-	-	-
Hälsövärd Tema A10 - NOK	1.9	2.7	4.7	5.2	-	-	-	-	-	-
Hälsövärd Tema B1 - SEK	1.9	2.7	4.7	5.2	3.6	3.6	3.5	-	-	-
Average yearly return, 2 yrs. %										
Hälsövärd Tema A1 - SEK	14.4	5.4	15.7	16.9	19.7	21.1	13.0	7.0	6.3	26.7
Hälsövärd Tema A1 - EUR	11.1	1.4	10.0	18.1	20.2	17.1	9.9	3.3	5.7	24.5
Hälsövärd Tema A1 - NOK	16.8	7.2	10.2	19.1	23.7	17.4	-	4.4	5.7	33.5
Hälsövärd Tema A9 - SEK	15.2	5.8	16.3	-	-	-	-	-	-	-
Hälsövärd Tema A9 - EUR	11.9	2.1	10.9	-	-	-	-	-	-	-
Hälsövärd Tema A10 - SEK	15.4	6.3	16.8	18.0	-	-	-	-	-	-
Hälsövärd Tema A10 - EUR	12.1	2.4	11.2	19.2	-	-	-	-	-	-
Hälsövärd Tema A10 - NOK	17.8	8.2	11.2	20.2	-	-	-	-	-	-
Hälsövärd Tema B1 - SEK	14.4	5.4	15.7	17.0	19.8	21.1	13.0	-	-	-
Comparison to index including dividends, %										
SEK	10.9	5.1	21.0	14.3	13.2	20.4	9.5	4.1	7.4	28.5
EUR	7.8	1.1	15.1	15.5	13.7	16.5	6.4	0.5	6.8	26.4
NOK	13.3	6.9	15.3	16.4	17.0	16.7	11.2	1.6	6.8	35.5
Average yearly return, 5 yrs. %										
Hälsövärd Tema A1 - SEK	14.8	14.5	16.8	17.7	13.2	13.3	15.8	20.1	19.8	20.9
Hälsövärd Tema A1 - EUR	13.2	12.4	13.9	16.1	11.1	11.0	12.7	16.8	18.0	20.5
Hälsövärd Tema A1 - NOK	16.9	15.2	15.5	18.4	13.0	12.9	-	23.8	21.8	25.7
Hälsövärd Tema B1 - SEK	14.9	14.5	16.8	17.8	13.2	13.3	15.8	-	-	-
Comparison to index including dividends, %										
SEK	13.3	13.5	15.8	15.4	9.1	12.5	14.7	19.2	20.0	22.6
EUR	11.7	11.4	13.0	13.8	7.0	10.2	11.7	16.0	18.3	22.2
NOK	15.4	14.2	14.6	16.0	8.9	12.1	15.5	23.0	22.1	27.4
Average yearly return, 10 yrs. %										
Hälsövärd Tema A1 - SEK	15.4	15.1	18.4	18.7	17.0	15.6	13.6	11.4	9.7	8.7
Hälsövärd Tema A1 - EUR	13.0	12.5	15.4	17.0	15.7	15.3	14.5	10.9	9.0	9.0
Hälsövärd Tema A1 - NOK	16.5	15.9	19.6	20.1	19.2	17.4	-	13.3	10.1	11.0
Hälsövärd Tema B1 - SEK	15.4	15.1	18.4	18.8	17.0	15.6	13.6	-	-	-
Comparison to index including dividends, %										
SEK	14.0	14.1	17.5	17.7	15.6	15.4	13.2	11.5	10.5	9.9
EUR	11.5	11.5	14.5	16.0	14.4	15.1	14.1	11.1	9.8	10.2
NOK	15.0	14.9	18.7	19.0	17.8	17.1	14.3	13.5	10.9	12.2
Dividends per unit, SEK										
Exchange rate EUR/SEK	11.35	11.13	11.12	10.30	10.05	10.51	10.13	9.83	9.58	9.16
Exchange rate NOK/SEK	0.99	0.99	1.06	1.03	0.96	1.07	1.02	1.00	1.06	0.95

Historically, the fund may have had share classes that have now been terminated and are not available under Fund facts - history. Therefore, both Number of units in total, thousands and Fund capital total can deviate from the sum of displayed share classes.

Benchmark: Solactive ISS ESG DM Health Care UCITS Index NTR

Up to 2019-04-30: MSCI World Health Care Net

The fund's benchmark represents a comparable reference with regard to the fund's investment focus, types of assets, markets or relevant sectors. In the event the fund issues dividends, performance is calculated with distributions added back.

Detailed information for the share classes' designation (nomenclature) is provided in the funds Prospectus.

Refer to the last pages for definitions.

Fund facts - costs

Max. allowed mgmt. costs in % according to fund rules

Hälsövärd Tema A1	1.50
Hälsövärd Tema A9	0.75
Hälsövärd Tema A10	0.60
Hälsövärd Tema B1	1.50

Collected mgmt. costs in % of average fund capital

Hälsövärd Tema A1	1.50
Hälsövärd Tema A9	0.75
Hälsövärd Tema A10	0.60
Hälsövärd Tema B1	1.50

Management fees and other administrative or operating costs, %

Hälsövärd Tema A1	1.51
Hälsövärd Tema A9	0.76
Hälsövärd Tema A10	0.61
Hälsövärd Tema B1	1.51

Transaction costs, SEK thousand

Transaction costs in % of turnover

Fund facts - other key figures

Turnover rate	0.3
Share of turnover conducted via closely-related securities companies in %	3.0
Share of turnover conducted between funds managed by Handelsbanken Fonder AB, %	0.0

Handelsbanken Hälsovård Tema, cont.

Risk and return measurements*

Total risk % - A1 SEK	10.9	Active return % - A10 NOK	4.6
Total risk % - A1 EUR	10.5	Active return % - B1 SEK	3.5
Total risk % - A1 NOK	11.7	Information ratio - A1 SEK	1.8
Total risk % - A9 SEK	10.9	Information ratio - A1 EUR	1.8
Total risk % - A9 EUR	10.5	Information ratio - A1 NOK	1.9
Total risk % - A10 SEK	10.9	Information ratio - A9 SEK	2.3
Total risk % - A10 EUR	10.5	Information ratio - A9 EUR	2.2
Total risk % - A10 NOK	11.7	Information ratio - A10 SEK	2.4
Total risk % - B1 SEK	10.9	Information ratio - A10 EUR	2.3
Total risk in index % - A1 SEK	10.6	Information ratio - A10 NOK	2.4
Total risk in index % - A1 EUR	10.6	Information ratio - B1 SEK	1.8
Total risk in index % - A1 NOK	11.0	Sharpe ratio - A1 SEK	1.1
Total risk in index % - A9 SEK	10.6	Sharpe ratio - A1 EUR	0.8
Total risk in index % - A9 EUR	10.6	Sharpe ratio - A1 NOK	1.2
Total risk in index % - A10 SEK	10.6	Sharpe ratio - A9 SEK	1.1
Total risk in index % - A10 EUR	10.6	Sharpe ratio - A9 EUR	0.8
Total risk in index % - A10 NOK	11.0	Sharpe ratio - A10 SEK	1.2
Total risk in index % - B1 SEK	10.6	Sharpe ratio - A10 EUR	0.9
Benchmark	Solactive ISS ESG DM Health Care UCITS Index NTR	Sharpe ratio - A10 NOK	1.3
Active Share %	40.8	Sharpe ratio - B1 SEK	1.1
Active return % - A1 SEK	3.4	Sharpe ratio in index - A1 SEK	0.8
Active return % - A1 EUR	3.3	Sharpe ratio in index - A1 EUR	0.4
Active return % - A1 NOK	3.5	Sharpe ratio in index - A1 NOK	0.9
Active return % - A9 SEK	4.3	Sharpe ratio in index - A9 SEK	0.8
Active return % - A9 EUR	4.2	Sharpe ratio in index - A9 EUR	0.4
Active return % - A10 SEK	4.5	Sharpe ratio in index - A10 SEK	0.8
Active return % - A10 EUR	4.3	Sharpe ratio in index - A10 EUR	0.4
		Sharpe ratio in index - A10 NOK	0.9
		Sharpe ratio in index - B1 SEK	0.8

* Risk statistics are based on historical monthly returns over two years. Refer to the last page for definitions. Total exposure in the fund is calculated in accordance with the commitment method. Total exposure in the fund is calculated in accordance with the commitment method.

Balance sheet, SEK thousand

	30 jun 2024	% of fund capital	31 dec 2023	% of fund capital
ASSETS				
Transferable securities	23,743,510	98.5	17,868,289	97.4
Total financial instruments with positive market value (Note 1)	23,743,510	98.5	17,868,289	97.4
Bank assets and other liquid assets	244,966	1.0	481,955	2.6
Prepaid expenses and accrued income	12,722	0.1	8,331	0.0
Other assets	155,617	0.6	-	-
Total assets	24,156,814	100.2	18,358,574	100.1
LIABILITIES				
Accrued expenses and prepaid income	26,923	0.1	22,078	0.1
Other liabilities	28,352	0.1	-	-
Total liabilities	55,275	0.2	22,078	0.1
Fund capital	24,101,539	100.0	18,336,496	100.0
ITEMS INCLUDED IN THE BALANCE SHEET				
Lended financial instruments	437,677	1.8	546,004	3.0
Collateral received for lended financial instruments	478,578	2.0	586,560	3.2

Note 1) for Balance sheet

Fund holdings in financial instruments

Transferable securities admitted to trading on a regulated market or equivalent market outside the EEA

98.1

	Number/Nominal amount in 1000's	Market value SEK t	% of fund capital
LISTED EQUITIES			
AUSTRALIA			
Telix Pharmaceuticals	675,000	89,036	0.4
		89,036	0.4
BELGIUM			
UCB	192,000	302,256	1.3
		302,256	1.3
DENMARK			
Novo Nordisk B	1,502,000	2,298,807	9.5
Zealand Pharma	332,000	450,976	1.9
		2,749,783	11.4
FRANCE			
Sanofi	633,000	646,181	2.7
		646,181	2.7

	Number/Nominal amount in 1000's	Market value SEK t	% of fund capital
GERMANY			
Evotec	640,000	65,195	0.3
Merck KGaA	84,000	147,539	0.6
Sartorius Pref	22,000	54,685	0.2
		267,418	1.1
IRELAND			
Alkermes	170,000	43,388	0.2
		43,388	0.2
JAPAN			
Chugai Pharmaceuticals	520,000	195,682	0.8
Daiichi Sankyo	1,508,260	548,512	2.3
Sysmex	827,000	141,068	0.6
Terumo	1,365,000	238,411	1.0
		1,123,673	4.7
NETHERLANDS			
Argenx	66,400	307,939	1.3
Merus	145,000	90,860	0.4
		398,799	1.7
SOUTH AFRICA			
Aspen Pharmacare	910,000	123,134	0.5
		123,134	0.5
SOUTH KOREA			
Samsung Biologics	17,000	95,085	0.4
		95,085	0.4
SWEDEN			
AstraZeneca	630,000	1,046,430	4.3
BioArctic B	405,000	92,664	0.4
Biotage	300,000	48,930	0.2
Camurus	172,000	103,200	0.4
Egetis Therapeutics	9,900,000	46,233	0.2
Sobi	465,000	131,874	0.5
Xvivo Perfusion	240,000	99,720	0.4
		1,569,051	6.5
SWITZERLAND			
Crispr Therap N	70,000	40,038	0.2
Lonza Group	46,600	269,323	1.1
Roche Holding	173,000	508,691	2.1
Sandoz Group	310,000	118,882	0.5
Tecan Group	24,300	86,143	0.4
		1,023,079	4.2
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND			
Bicycle Therapeutics	200,000	42,869	0.2
GSK	1,550,000	317,371	1.3
		360,240	1.5
UNITED STATES OF AMERICA			
Abbott Laboratories	580,000	638,248	2.6
AbbVie	455,000	826,476	3.4
Amgen	227,200	751,784	3.1
Boston Scientific	751,000	612,479	2.5
Cencora	245,500	585,756	2.4
DexCom	270,000	324,194	1.3
Edwards LifeSciences	554,000	541,932	2.2
Eli Lilly	250,350	2,400,395	10.0
Halozyme Therapeutics	485,000	268,934	1.1
HCA Holdings	160,500	546,088	2.3
Immunome	230,000	29,473	0.1
IQVIA Holdings	117,000	261,985	1.1
Johnson & Johnson	566,000	876,091	3.6
Krystal Biotech	100,000	194,478	0.8
Madrigal Pharmaceuticals	28,000	83,075	0.3
Merck & Co	1,020,000	1,337,288	5.5
Natera	74,000	84,864	0.4
Paragon 28	350,000	25,353	0.1
Regeneron Pharmaceuticals	42,959	478,160	2.0
Royal Pharm A	430,000	120,083	0.5
Thermo Fisher Scientific	200,000	1,171,276	4.9
United-Health Group	325,000	1,752,779	7.3
Vertex Pharmaceuticals	144,800	718,764	3.0
Zimmer Biomet	185,000	212,631	0.9
		14,842,586	61.6
Listed equities		23,633,709	98.1

Transferable securities that are traded regularly on any other market which is regulated and open to the public

0.5

	Number/Nominal amount in 1000's	Market value SEK t	% of fund capital
LISTED EQUITIES			
SWEDEN			
Nanoform Finland	1,025,000	19,229	0.1
Surgical Science Sweden	724,000	90,572	0.4
		109,801	0.5
Listed equities		109,801	0.5
Total financial instruments with positive market value		23,743,510	98.5
Total financial instruments with negative market value		0	0.0
Net, other assets and liabilities		358,029	1.5
Total fund capital		24,101,539	100.0

The numbers in the tables are rounded to the nearest thousand and first decimal point, respectively, which may result in an amount in the summation of the columns that differs from the final total.

Handelsbanken Hälsovård Tema, cont.

Information about the fund's securities lending

Volume of lent securities , SEK thousand:	437,677
--	----------------

Volume of lent securities as a % of total lendable assets	1.8
--	------------

The ten largest issuers of collateral for securities lending per issuer, SEK thousand:

U.S.A.	262,675
France	24,224
United Kingdom	16,914
Belgium	5,585
BHP Group	5,226
Unilever	4,331
Sony	4,331
Zijin Mining Group Zijin Mining	4,294
Shin-Etsu Chemical	4,293
Softbank Group	4,293

The largest counterparties for securities lending, SEK thousand

Morgan Stanley & Co. International	133,094
Barclays Bank	107,712
UBS, London Branch	86,615
Citigroup Global Markets	38,904
SEB	32,334
BNP Paribas Financial Markets	25,200
Goldman Sachs International	18,583
Merrill Lynch International	17,813
Barclays Capital Securities	14,752
HSBC Bank	2,028

Type and quality of collateral, SEK thousand

Bonds and other interest-bearing instruments	319,283
Equities, shares	159,295
	478,578

We accept government bonds and treasury bills with a rating of AA- from S&P or Aa3 from Moody's or higher issued by the United States, the United Kingdom, states within the eurozone (Austria, Belgium, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal and Spain) as well as Australia, Canada, Denmark, Japan, New Zealand, Norway, Sweden and Switzerland. We also accept equities in major and well-known indexes as collateral.

Profile of the collateral's duration, SEK thousand:

Less than 1 day	-
1 Day to 1 Week	-
1 Week to 1 Month	2
1 Month to 3 Months	3,602
3 Months to 1 Year	5,177
Above 1 Year	310,503
Open Maturity	159,295
	478,578

The domicile of the counterparties, SEK thousand:

Frankrike	25,200
United Kingdom	419,501
Sweden	33,878
	478,578

Currency of the collateral , SEK thousand:

AUD	10,661
CAD	0
CHF	494
DKK	18
EUR	41,343
GBP	36,387
HKD	7,626
JPY	62,889
NOK	1
NZD	31
SEK	25
SGD	1,169
USD	317,934
	478,578

Settlement and clearing, SEK thousand:

Triparty	478,578
	478,578

The profile of the duration for securities lending is undetermined, but may be immediately terminated.

The collateral received is held by J.P. Morgan Bank Luxembourg S.A. or another group and is not reused.

Information about returns and expenses:

Securities lending for the full year generated a total revenue of SEK 3,539 thousand of which 80% was passed on to the fund and 20% to J.P. Morgan Bank Luxembourg S.A. in its role as the intermediary of securities lending.

Counterparties for securities lending during the year:

- Barclays Bank
- Barclays Capital Securities
- BNP Paribas Financial Markets
- Citigroup Global Markets
- Goldman Sachs International
- Handelsbanken
- HSBC Bank
- J.P. Morgan Securities
- Merrill Lynch International
- Morgan Stanley & Co
- SEB
- UBS, London Branch

Information from Handelsbanken Fonder AB

Management Company's Board of Directors, CEO, Auditors and Personnel

As of June 30, 2024

Handelsbanken Fonder AB

Board of Directors

DANIEL ANDERSSON, Chairman

Executive Vice President, Svenska Handelsbanken AB (publ), Head of the Handelsbanken Savings and Financing

MALIN HEDMAN BJÖRKMO

Consultancy specializing in corporate governance and financial regulations

HELEN FASTH GILLSTEDT

Managing Director and owner of a management consultancy firm

LARS SEIZ

Strategic advisor in asset management

ÅSA HOLTMAN ÖHMAN

Employee representative for the Union of Financial Sector Employees, Regional section, CHK club, Svenska Handelsbanken AB (publ)

Chief Executive Officer

MAGDALENA WAHLQVIST ALVESKOG

Management Company's auditors

Elected at the Annual General Meeting

PRICEWATERHOUSECOOPERS AB, PETER NILSSON

Personnel and organisation

The Management Company is a wholly-owned subsidiary of Svenska Handelsbanken AB (publ).

Key members of management within Handelsbanken Fonder AB are as follows:

Chief Executive Officer

MAGDALENA WAHLQVIST ALVESKOG

Head of Sustainability

AURORA SAMUELSSON

Deputy Chief Executive Officer

EMMA VIOTTI

Head of Products and Communications

EMMA VIOTTI

Chief Operating Officer

CARINA ROECK HANSEN

Head of Compliance

MONIKA JENKS

Head of Risk

FREDRIK ALHEDEN

Head of Sales

STEFAN BLOMÉ

Head of Corporate Governance and Board secretary

STAFFAN RINGVALL

CIO Active Asset Management

KATARINA PASCHAL

Head of Legal

FREDRIK KÖSTER

CIO Passive Asset Management and Asset Allocation

PÄR SJÖGEMARK

Post address: SE-106 70 STOCKHOLM

Telephone: +46-8-701 10 00

Information from Handelsbanken Fonder AB

Corporate Governance

Handelsbanken Fonder exercises an active ownership role. The purpose is to participate so that the Company takes decisions that lead to a sustainable and positive value growth, which in turn benefit our unit holders. We view our ownership role from a long-term perspective, given that changes in companies often take time to implement. As a guideline for our actions, the Board of Directors of Handelsbanken Fonder has adopted a Policy for shareholder engagement and responsible investments. Our work is also guided by those principles established in the Swedish Corporate Governance Code. The Management Company's work in nomination committees is also regulated by the Guidelines for nomination committees.

An essential channel is the regular contacts that our portfolio managers have with those companies in which we invest or intend to invest. This provides a very good opportunity to present our views on the performance demonstrated by the companies. We emphasize good corporate governance, sustainability and transparency at the companies in which we invest.

Handelsbanken Fonder AB participates in a number of nomination committees where we have a sufficiently large ownership to be able to influence the recommendations to the composition of the board of directors. The board shall have extensive and relevant competence and its composition shall be characterized by different perspectives. We work actively for a more equal distribution of genders in the boards. The management companies ambition is to vote at the annual general meetings where we have significant ownership and where our votes could impact the course of events, which is normally over approximately 0.5 per cent of the votes.

We participate in a substantial number of annual meetings each year, in the Nordics, but also in other countries where we have a substantial ownership. In some cases, companies request a dialogue with shareholders prior to a proposal being presented at the annual meeting to gain support for the proposal by the major shareholders.

Handelsbanken Fonder AB participates in such discussions to the extent we have been invited and presents our views that aim at achieving a favourable result for unit holders.

The Management Company's Policy for shareholder engagement and responsible investments is available on our website at: <https://www.handelsbanken.se/sv/om-oss/svenska-dotterbolag/handelsbanken-fonder/our-work>.

Responsible Investments

Handelsbanken Fonder's vision is to create financial wealth and planetary health through sustainable investments. In order to clarify our path to achieving this, we have established sustainability goals, constituting part of Handelsbanken Group's obligations under the UN Principles for Responsible Banking, which the Bank signed in 2019, and the fund company's obligations according to the Net Zero Asset Managers (NZAM) initiative. The purpose of setting quantitative goals is to ensure measurable results, and also allow our stakeholders to follow our development. The goals encompass all of our funds, and relate to two main areas.

Paris-aligned investment portfolios

- 50 per cent reduction in our funds' emission intensity by 2030.
- doubling of investments in climate-related solutions by 2030.

Increase our contribution to the 2030 Agenda for Sustainable Development

- increase the proportion of sustainable investment by 30 per cent by 2025.
- increase engagement activities with a positive outcome every year until 2025.

Handelsbanken Fonder's sustainability work is guided by our Policy for shareholder engagement and responsible investment. The Policy describes the starting point for integration of sustainability, our undertakings in terms of Global Compact, the Principles for

Responsible Investment (PRI) and international norms and conventions. It also describes the methods for sustainability applied in the asset management and principles of our corporate governance. Read more about this in the reports for each individual fund and in the Management Company's Policy for shareholder engagement and responsible investments that is available at: <https://www.handelsbanken.se/sv/om-oss/svenska-dotterbolag/handelsbanken-fonder/our-work>.

Accounting and valuation principles

The Annual Report is drawn up in accordance with generally accepted accounting principles. The accounting principles for the securities funds are based on the Swedish Investment Funds Act (2004:46) and on the Alternative Investment Fund Managers Act (2013:561) for our non-UCITS funds, ESMA's guidelines. The principles are also based on the Swedish Investment Fund Association's Guidelines for Key Ratio Accounting of Swedish UCITS and non-UCITS funds as well the Financial Supervisory Authority's regulations regarding Swedish UCITS funds (FFFS 2013:9) and the Financial Supervisory Authority's regulations regarding alternative investment fund managers (FFFS 2013:10) for our non-UCITS funds. Further, applicable provisions in the Swedish Accounting Act are also applied. Accounting is based on the transaction date.

Valuation principles

Financial instruments, assets and liabilities are valued at market value.

Equities and equity-related instruments are valued primarily at the official closing price, thereafter at the latest trading price from the same day as the time of the valuation.

Interest-bearing securities are valued primarily at the bid price. Swedish government bonds and covered bonds are valued primarily at the median mid-yield.

Interest rate and currency derivatives that are not exchange-traded are valued in accordance with generally-accepted valuation models.

In the event a reliable price is unavailable, alternatively the instrument is not regularly traded, a valuation model can be utilized. This also applies when an instrument that is normally valued through the use of a market price is no longer deemed to have a reliable price.

Financial instruments, assets and liabilities that are revalued to the fund's portfolio currency are recalculated based on the official closing exchange rate on the balance sheet date.

Foreign withholding taxes

Due to the changes in the tax regulations for Swedish funds on January 1, 2012, as well as the developments within taxation, there is significant uncertainty with regard to the application of withholding taxes on equity distributions. This can result in both higher revenues and increased expenses regarding withholding taxes in funds with foreign holdings. The revenues or expenses will be reported when received or paid, respectively. The distributions will be reported in the amount actually received, although it cannot be ruled out that the withholding taxes can be revised, which would result in an additional withholding tax on the previously received distributions made in the fund. A remittance (repayment of withholding tax paid) is reported when received. With regard to restitution for certain funds and from certain countries, e.g., Denmark and Finland, the principle of reporting restitution when received or paid can be waived if there are tax and reporting grounds for doing so.

More information

You will find the complete information brochure with fund rules, fact sheets and current share price performance on our website at www.handelsbanken.se/funds. For further information on the subscription and redemption of fund units, please contact your local Handelsbanken branch office.

Definitions

Fund statistics

Average fund capital – Calculated as the mean value of the fund's net asset value during the year (or that portion of the year during which the fund existed). The fund's net asset value is calculated on a daily basis.

Average yearly return, 2, 5 and 10 years, respectively – The fund's average effective annual yield during the last 2, 5 or 10 years, respectively.

Collected management costs in % of average fund capital – Actual management fees collected. Expenses are calculated daily and represent costs for management, administration, marketing and distribution. Expressed in percent of the average fund capital and calculated on a rolling 12-month basis.

Costs for monthly savings SEK 100 – Total costs charged to a unit holder who had SEK 100 invested on the first banking day of each month during the year and retained the investment throughout the year. Calculated for the full year only and for funds and share classes that have existed during the full year. The corresponding amount for funds with EUR as the base currency is EUR 10. The corresponding amount for funds with NOK as the base currency is NOK 100.

Costs for one-time subscription SEK 10 000 – Total costs charged to a unit holder who had SEK 10 000 invested in the fund at the beginning of the year and retained the investment throughout the year. Calculated for the full year only and for funds and share classes that have existed during the full year. The corresponding amount for funds with EUR as the base currency is EUR 1 000. The corresponding amount for funds with NOK as the base currency is NOK 10 000.

Dividends per unit – The Management Company determines the amount of the dividend to be paid to fund unit holders of the distribution share class on an annual basis. Distributions are paid to those fund unit holders registered for distribution shares on the distribution date determined by the Management Company.

Duration – The duration of a fund is a measure of how sensitive the fund is to changes in interest rates. Simply stated, it is the weighted average of the residual maturity in the fund's investments. Measured in years or months.

Fund capital – The fund's net asset value on the closing date for the respective year.

Fund's total net flow – Subscriptions less redemptions in the fund, excluding reinvested dividends and any flows from mergers.

Index – The index used by the fund as its benchmark.

Index incl. dividends – Performance of the fund's benchmark during the respective year. Performance is expressed in percent and is converted to the currency for each share class in those cases where the index is published in another currency. The table shows the index including dividends.

Management fees and other administrative or operating costs – From the 1 of January management fees and other administrative or operating costs replace ongoing charges. The cost measurement includes management fee and refer to the ongoing costs in the fund, excluding transaction costs for securities, interest expenses, transaction-related tax expenses and any performance-based fees.

When the fund engages in security lending, 80% of the revenue earnings derived from the lending agreement is allocated to the fund whilst the remaining 20% is allocated to the securities lending agent. Given that the revenue allocation agreement increases the fund's costs, the remuneration paid to the securities lending agent will be included in the management fees and other administrative or operating costs.

The measure is based on the fees deducted from the fund during the period. It is expressed as a percentage of the average fund capital and calculated on a rolling 12-month basis.

A supplement for the underlying fund's most recently available management fees and other administrative or operating costs, after deducting for discounts received, will be added for funds that invest in other funds.

Net asset value – Net asset value expressed as the rate prevailing on the balance sheet date for the respective year.

Number of units – The number of outstanding units on the last banking day for the respective year. Reported in thousandths of units.

Other assets in the balance sheet contain receivables for unsettled trades, received after balance sheet date. This applies to both sold securities and issued fund shares.

Other costs in the income statement include transaction costs, taxes and bank costs.

Other financial costs in the income statement include expenses for security lending.

Other financial income in the income statement includes premiums for security lending and discounts for management costs in underlying funds.

Other income in the income statement

refers to money paid back for bank charges and taxes.

Other liabilities in the balance sheet contain liabilities for unsettled trades, paid after balance sheet date. This applies to both purchased securities and redemption of fund shares.

Other techniques and instruments – Techniques and instruments used to improve the effectiveness of fund management refers to the following: techniques and instruments are attributable to transferable securities and money market instruments used in a cost-effective manner to lower risks and expenses or to increase returns in the fund with a risk level that is consistent with the fund's risk profile and applicable rules for the distribution of risk. Example of techniques and instruments include securities lending and agreements on the repurchase of securities sold, i.e., repos and reverse repo transactions.

Risk – The calculation of the fund's risk is the same for all EU member states. 1 is for the lowest risk (small price fluctuations) and 7 is for the highest risk (risk for substantial price fluctuations). The classification is based on the standard deviation (volatility) for the fund, calculated using the unit values over a five-year period. If five years of performance is not available, the standard deviation for the relevant comparable index or other benchmark will be used. Risk describes primarily market risk and currency risk.

Share classes – A fund can have several share classes. Different share classes have different conditions, e.g., currency, with dividends or without, management fee or an initial minimum subscription amount. Fund capital is the same for the share classes and therefore information refers to the fund as a whole unless stated otherwise. Fund units within each individual share class are the same size and have the same rights to the assets included in the fund. The distribution in a distribution share class impacts the relationship between the value of units that are non-distribution and the value of the units that are distribution, with the value of the distribution fund units decreasing in relation to the size of the distribution.

Share of turnover conducted via closely related securities companies – The proportion of fund purchases and sales of financial instruments conducted by Handelsbanken in terms of value. Expressed in percent of the fund's total turnover.

Share of turnover conducted between funds managed by the same fund management company – The proportion of fund purchases and sales of financial instruments

conducted on behalf of the securities fund from another fund managed by the same fund management company. Expressed in percent of the fund's total turnover.

Total returns – Reports how the value of a unit has changed during the respective year. If the fund has paid dividends during the year the change in value has been calculated as though the dividend or contribution before tax was added back on the distribution date. Annual return is measured in percent from the date of the previous year's closing date to the closing date for the respective year. Returns for the semi-annual review are reported for the first half of the current year.

Transaction costs – Expressed partly as an amount and partly as a percentage of the value of the financial instruments turned over. The value refers to the overall market value, but for futures and future related instruments the value refers to the exposure value. Calculated on a rolling 12-month basis. Reported in the Income Statement under the heading "Other expenses". Examples of transaction costs are brokerage and derivative costs.

Turnover rates (general principle) – The fund's turnover rate calculated, on the one hand, as the ratio between the lowest total amount for securities purchased or sold during the year and, on the other hand, as the average fund capital during the same period. With regard to equity funds, fixed income securities with a residual maturity of a maximum of 397 days at the time of acquisition are excluded from purchased or sold securities. The turnover rate is reported as the number of times turned over per year and is calculated on a rolling 12-month basis.

Turnover rate (leveraged funds) – If a fund has traded with derivative instruments during the period and the turnover calculation conducted in accordance with the general principle makes the turnover information appear misleading, the fund's turnover rate is also calculated by decreasing the total of purchased and sold financial instruments during the period by the total of the subscribed and redeemed units in the fund. This amount is divided by the fund's average fund capital during the period. Negative turnover arises when the total amount for purchased and sold fund units exceeds the total amount for purchased and sold derivatives.

Volume of lent securities as a % of total lendable assets – Is the market value of lent securities as of the balance sheet date divided by the market value of the fund's financial instruments with positive market value.

Key figures for risk follow-up

In order to obtain relevant comparisons, dividends have been reinvested in the funds and their respective benchmarks. All key figures have also been calculated on the basis of the Annual effective yields. The values for the past two years have been used for the majority of the funds. A risk forecast has been made for more recent funds, with fund holdings as of balance sheet date as the basis. In these cases, historical data for relevant reference portfolios is used for the calculation of the risk forecast.

Active return states the annual over- or under effective return attained by the fund in comparison to its benchmark.

Active Share compares the equity fund's holdings with the holdings in its benchmark. The key figures are stated in percent, from 0% (exact same distribution as the index) to 100% (none of the holdings are included in the index). The measurement is calculated as one-half of the sum of the absolute deviations between a securities' weighting in the fund and its weight in the index.

Information ratio is a measure of the active returns attained by the fund when deviating from its benchmark. It is the ratio between the active returns and the tracking error. A negative information ratio means that the

fund has underperformed its benchmark.

Index shows the average returns on the underlying market in which the fund invests.

Sharpe ratio/Sharpe ratio in index is a measure of the fund/index's return, taking into consideration the risk of the fund/index. A high return attained at a lower risk is better than an equivalent return attained at a high risk. Calculated, on the one hand, as the ratio between the return, less the risk-free interest (interest on government securities) and, on the other hand, as the total risk of the fund/index. The Sharpe ratio is the most relevant ratio for comparing.

Spread exposure is shown for fixed income funds, as of the closing date, and is a measure of credit risk. The spread exposure

shows how much the fund will depreciate, in percent of the value of the fund, if the spread between the value of a fixed income fund and government bonds is doubled. Calculated as capital-weighted credit duration multiplied by the spread of the instrument (differential) compared to the government yield curve.

Tracking error measures the standard deviation of the difference in the yields between the fund and its benchmark (the variation in the relative yields). The historical tracking error indicates how much the fund's yield has deviated from benchmark.

Total risk/Total risk in index is stated as the standard deviation for variations in the monthly yields of the fund/index. The higher the number, the higher the risk.

VaR is a parametric in this case and is calculated in accordance with the covariance method. The covariance matrix is presented by the risk system and is updated on a monthly basis. The confidence level is 95% and the time horizon is one day.

Abbreviations

A number of abbreviations are used for certain securities in the table of contents:

ADR	American Depository Receipt	IR	Redemption Right
ADS	American Depository Share	KV	Convertible
BTA	Interim Share	NVDR	Non-Voting Depository Receipt
CB	Callable Bond	Pref	Preference Share
ETF	Exchange Traded Fund	SDB	Swedish Deposit Certificate
f/r	Foreign Registered	TO	Warrants
FRN	Floating Rate Note	TR	Subscription Right
GDR	Global Depository Receipt		

[The prospectus, fund rules and fact sheets for each fund are available in the mutual fund price list at handelsbanken.se/funds.](#)

Handelsbanken Fonder AB is a wholly-owned subsidiary of Svenska Handelsbanken AB (PLC).

About risk

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. Summary of investors' rights, prospectus, fund rules and KID are available under each fund at [handelsbanken.se/funds](#).